Published on 26 May 2023 on Zacks via Yahoo Finance

Regeneron (REGN) Posts Upbeat Data From Multiple Myeloma Study

Regeneron REGN announced updated data from a pivotal phase II study evaluating its investigational BCMAxCD3 bispecific antibody, linvoseltamab, in patients with heavily pre-treated, relapsed/refractory (“R/R”) multiple myeloma.

Data from the study demonstrated that treatment with a 200mg dose of linvoseltamab led to early, deep and durable responses in myeloma patients. With a median follow-up of six months, patients who received the recommended 200mg dose of linvoseltamab showed a 71% objective response rate (“ORR”). This includes 59% patients achieving very good partial response (“VGPR”) or better and 30% patients achieving a complete response (“CR”) or stringent complete response (“sCR”). Management also announced that the median progression-free survival was not reached.

Treatment benefit with linvoseltamab was also observed across prespecified subgroups, including patients with high disease burden and aggressive disease.